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Overview
Pregnancy is generally considered to be an immunosup-
pressed state; however, the impact of pregnancy on mothers
with viral hepatitis (Table 1) and the impact of viral hepati-
tis on fetuses/infants (Table 2) are not the same for all types
of hepatitis.
Pregnant women with acute hepatitis due to hepatitis E
virus (HEV) or herpes simplex virus (HSV) have an
increased risk of acute liver failure compared to persons
who are not pregnant. Flares of chronic hepatitis B may
occur during pregnancy and in the postpartum period, but
hepatic decompensation is rare.
The risk of vertical transmission of hepatitis viruses is
higher in pregnant women with acute versus chronic infec-
tion. In general, the risk is not increased with amniocente-
sis, fetal monitoring, or vaginal birth, and cesarean should
not be recommended to prevent transmission of hepatitis
viruses.1 Breastfeeding is safe for women with chronic hepa-
titis B virus (HBV) or chronic hepatitis C virus (HCV) infec-
tions—unless they have cracked nipples.2,3 Hepatitis A and
B vaccines are safe to be administered during pregnancy.
Hepatitis A Virus
Hepatitis A virus (HAV) infection does not progress to
chronic infection, and HAV is generally transmitted via
fecal-oral route; therefore, maternal-infant transmission is
rare. The highest risk of gestational complications such as
premature rupture of membrane, placental separation, or
preterm labor is during the second half of pregnancy
(Table 1).
Hepatitis B Virus
Neither acute nor chronic hepatitis B virus (HBV) infec-
tion poses a risk to fetal development. Flares of chronic
hepatitis B had been reported during pregnancy and in the
postpartum period. These flares are usually mild and in
some instances may be accompanied by the spontaneous
loss of hepatitis B e antigen (HBeAg).5
In the absence of prophylaxis, the risk of vertical trans-
mission is up to 90%.6 The risk is higher if the mother is
HBeAg-positive or has high serum HBV DNA levels.
Perinatal transmission of HBV results in chronic infection
in 90% of infants; therefore, screening of all pregnant
women for hepatitis B surface antigen (HBsAg) at the first
antenatal visit to identify those who test positive is critical.
As of 2012, 181 countries worldwide have adopted univer-
sal HBV vaccination (regardless of maternal HBsAg status)
for all newborns. In most countries, babies born to HBsAg-
positive mothers will additionally receive one dose of hepa-
titis B immune globulin (HBIG) at a different site from the
first dose of HBV vaccine within 12 hours of birth. Passive-
active prophylaxis reduces the incidence of maternal-infant
transmission of HBV to 5% to 10%. The infant should be
tested for HBsAg and antibody to HBsAg 1 to 2 months
after completing the vaccine series to confirm immunity and
to rule out infection.
High maternal serum HBV DNA is a major cause of pro-
phylaxis failure. Administration of an oral antiviral to moth-
ers with high serum HBV DNA during the third trimester of
pregnancy has been shown to decrease the incidence of
prophylaxis failure (Table 3). Lamivudine was used in most
studies but is a pregnancy class C drug, whereas telbivudine
and tenofovir are pregnancy class B drugs. Data in the anti-
retroviral registry showed that the use of lamivudine and
tenofovir during pregnancy, even in the first trimester, did
not result in an increased incidence of birth defects.
Although the antiviral drug is used for a short duration in
this setting, given the high HBV DNA levels, tenofovir is
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preferred to minimize the risk of antiviral drug resistance.
There is no consensus on when to initiate, when to discon-
tinue, or what cutoff HBV DNA level should be used to ini-
tiate antiviral therapy. Most experts agree that antiviral
therapy should be considered when maternal HBV DNA
is> 7 to 8 log10 IU/mL, and treatment should be started
around week 28 to 32 of pregnancy to allow time for the
virus to be suppressed. Treatment may be stopped after
delivery if the goal of antiviral therapy is to decrease the
incidence of perinatal transmission. Tenofovir is a prodrug,
and the concentration in breast milk is 4.7% of that in
serum.7,8 Limited data suggest that breastfeeding is permis-
sible for mothers receiving tenofovir. Hepatitis flares may
occur after antiviral therapy is discontinued, and the moth-
ers should be closely monitored for 6 months after treat-
ment is stopped.
Fig. 1 shows an algorithm for managing women with
chronic HBV infection who are contemplating pregnancy.
Prior to pregnancy, pegylated interferon (PEG-IFN) may be
considered because of its finite duration. Among the oral
antivirals, tenofovir is the preferred drug because of its high
barrier to resistance and demonstrated safety in pregnancy.
Hepatitis C Virus
Vertical transmission of hepatitis C virus (HCV) occurs in
approximately 5% of newborns born to HCV-infected moth-
ers; the risk is higher if the mother is coinfected with HIV9
or has high HCV RNA level. Diagnosis of HCV infection in
the infant can be performed by testing for HCV RNA. If
HCV antibody (anti-HCV) is tested, it should be delayed
until the infant is at least 12 months of age.1 Approximately
60% to 80% of infected infants will develop chronic
infection.
Treatment of HCV should not be offered during preg-
nancy because ribavirin is a pregnancy class X drug that is
highly teratogenic, and interferon is a class C drug. There
are no data on safety of direct-acting antiviral agents in
pregnancy. Currently, there is no means to prevent mater-
nal-infant transmission of HCV.
Hepatitis E Virus
Hepatitis E virus (HEV) is usually spread via fecal-oral
route; however, ingestion of undercooked pork or exposure
to boar or wild pigs had also been reported to be a source
of HEV infection in developed countries.11
Acute hepatitis E is self-limiting in the vast majority of
cases, but hepatitis E during pregnancy can cause severe
hepatitis and acute liver failure, especially when it occurs
in the third trimester. Maternal fatality of 16% to 20%
had been reported when hepatitis E occurs in the third
trimester of pregnancy12,13 and is caused by acute liver
failure, eclampsia, or hemorrhage. A vaccine has been
developed for hepatitis E, but it is not available in most
countries.
Herpes Simplex Virus
Herpes simplex virus (HSV) infection during pregnancy is
rare but can cause disseminated infection, HSV hepatitis,
and acute liver failure, especially when the infection occurs
in the third trimester of pregnancy. Primary as well as latent
HSV infection—and both HSV-1 and HSV-2—can cause
hepatitis and acute liver failure. Patients typically present
with fever and markedly elevated aminotransferases. Skin
TABLE 1 Risks of Viral Hepatitis in Pregnant Women
Type of Viral
Hepatitis Potential Risks to Mother
Timing of Pregnancy
With Highest Risk
Hepatitis A Gestational complication;
preterm labor
2nd half of pregnancy,
especially 3rd trimester
Hepatitis B* Flares of chronic hepatitis B Can occur during pregnancy
or postpartum period
Hepatitis C* None
Hepatitis E Acute liver failure; eclampsia 2nd and 3rd trimester
HSV hepatitis Acute liver failure 3rd trimester
*Data based on pregnant women with chronic infection.
TABLE 2 Risks of Viral Hepatitis on Fetus/Infant and Preventive Measures
Potential Risks to Fetus=Infant Preventive Measures
Hepatitis A Fetal ascites; meconium peritonitis. Rare, mainly if mother
is infected during 1st trimester
Vaccinate pregnant women who will be traveling to endemic areas
Administer immune globulin to pregnant women who had contact
with persons with acute hepatitis A
Hepatitis B Perinatal infection. Risk higher if mother is HBeAg1 or
has high HBV DNA
Passive/active prophylaxis. HBIG and HBV vaccination within
12 hours of birth for all newborns of HBsAg1 mothers
Antiviral therapy for mothers with high HBV DNA in 3rd trimester of pregnancy
Hepatitis C Perinatal infection. Risk higher if mother is coinfected with
HIV or has high HCV RNA
None
Hepatitis E Spontaneous abortion; premature delivery. Risk higher if
mother is infected during 3rd trimester
None
HSV hepatitis Neonatal HSV: Skin lesions, keratoconjunctivitis, cataracts,
chorioretinitis, ulcerative lesions in mouth/tongue,
central nervous system disease, disseminated HSV
(hepatitis, hemorrhagic pneumonitis, necrotizing
enterocolitis, meningoencephalitis)
Treat mother with primary or first episode of genital HSV infection with acyclovir
Consider suppressive therapy for recurrent infections at 36 weeks of pregnancy
Consider cesarean section delivery if predicted risk of transmission is high
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lesions may be seen in 30% of patients. Diagnosis can be
made by PCR testing for HSV DNA. Treatment is with acy-
clovir or valacyclovir, which are pregnancy class B drugs.
Clinical vigilance, prompt diagnosis, and treatment are criti-
cal because treated patients have lower rates of liver trans-
plantation or death compared to untreated patients (55% vs
88%).14 Risk of vertical transmission is highest in women
who have a primary infection at the time of delivery
(40%-44%), followed by having a first episode of genital
nonprimary infection (24%-31%) and recurrent infections
(1.3%-3%). Intrauterine infection is rare (1 in 250,000).
Eighty-five percent of infection occurs in the perinatal
period and 10% in the postnatal period. Invasive fetal mon-
itoring, prolonged duration of ruptured membrane, and
vaginal delivery increase the risk of vertical transmission.
Cesarean is recommended in select cases. n
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TABLE 3 Clinical Studies of Oral Antiviral Therapy in HBsAg1 Pregnant Women to Decrease Risk of Perinatal Transmission of Hepatitis B
Author, Year, Country (ref) Study Design
No. of
Pregnant Women
Maternal
HBV DNA
Antiviral Drug and
Start Time During
Pregnancy
% Infants HBsAg1Ve
Treated vs Control
(time of assessment) P Value
WM Xu et al, 2009, China15 Randomized
double-blinded,
placebo controlled
56 treatment vs
59 placebo
> 109 cp/ml Lamivudine
week 32
18% vs 39% (52 week) 0.014 (intention
to treat analysis) vs
0.37 (per protocol
analysis)
GR Han et al, 2011, China16 Prospective,
not randomized
135 treatment vs
94 untreated control
> 107 cp/ml Telbivudine
weeks 20-32
0% vs 8% (28 week) 0.001
CQ Pan et al, 2012, China17 Prospective,
open-label
53 treated vs
35 untreated control
> 106 cp/ml Telbivudine
weeks 12-30
0% vs 8.6% (28 week) 0.03
MK Celen et al, 2013, Turkey18 Retrospective 45 treatment vs
24 controls
> 107 cp/ml Tenofovir
weeks 18-27
0% vs 8% (28 week) 0.022
*All pregnant women were HBeAg1 and all newborns received HBIG1HBV vaccine
Figure 1 Management of HBV in women contemplating pregnancy. *Effec-
tive contraceptive indicated. Abbreviation: NUC, nucleos(t)ide analogue.
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